mTOR inhibitor-associated proteinuria in kidney transplant recipients

Transplantation Reviews

Volumn 26, Issue 1, 2012, Pages 27-29

  Diekmann, Fritz ^a   Andrés, Amado ^b   Oppenheimer, Federico ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; DACLIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ALLOGRAFT; DELAYED GRAFT FUNCTION; DRUG MECHANISM; DRUG SUBSTITUTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY TRANSPLANTATION; MEDICAL LITERATURE; POSTOPERATIVE PERIOD; PROTEINURIA; REVIEW;

EID: 82955226337     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2011.10.003     Document Type: Review

References (26)

1. Diekmann F., Gutierrez-Dalmau A., Lopez S., et al. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Nephrol Dial Transplant 2007, 22:2316-2321.
2. Franco A.F., Martini D., Abensur H., Noronha I.L. Proteinuria in transplant patients associated with sirolimus. Transplant Proc 2007, 39:449-452.
3. Vogelbacher R., Wittmann S., Braun A., Daniel C., Hugo C. The mTOR inhibitoreverolimus induces proteinuria and renal deterioration in the remnant kidney model in the rat. Transplantation 2007, 84:1492-14999.
4. Aliabadi A.Z., Pohanka E., Seebacher G., et al. Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients. Am J Transplant 2008, 8:854-861.
5. Pinheiro H.S., Amaro T.A., Braga A.M., Bastos M.G. Post-rapamycin proteinuria: incidence, evolution, and therapeutic handling at a single center. Transplant Proc 2006, 38:3476-34788.
6. Straathof-Galema L., Wetzels J.F., Dijkman H.B., Steenbergen E.J., Hilbrands L.B. Sirolimus-associated heavy proteinuria in a renal transplant recipient: evidence for a tubular mechanism. Am J Transplant 2006, 6:429-433.
7. Stephany B.R., Augustine J.J., Krishnamurthi V., et al. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 2006, 82:368-374.
8. Roodnat J.J., Mulder P.G.H., Rische-Vos J., et al. Proteinuria after renal transplantation affects not only graft survival but also patient survival. Transplantation 2001, 72:438-444.
9. Dantal J., Berthoux F., Moal M.C., et al. Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial. Transplant Int 2010, 23:1084-1093.
10. Halimi J.M., Laouad I., Büchler M., et al. Early low-grade proteinuria: causes, short-term evolution and long-term consequences in renal transplantation. Am J Transpl 2005, 5:2281-2288.
11. Kahan B.D. Two-year results of multicenter phase III trials on the effect of the addition of sirolimus to cyclosporine-based immunosuppressive regimens in renal transplantation. Transplant Proc 2003, 35(Suppl 3A):37S-51S.
12. Groth C.G., Backman L., Morales J.M., et al. Sirolimus (rapamycin)-based therapy in human renal transplantation. Transplantation 1999, 67:1036-1042. for the Sirolimus European Renal Transplant Study Group.
13. Kreis H., Cisterne J.M., Land W., et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000, 69:1252-1260. for the Sirolimus European Renal Transplant Study Group.
14. Büchler M., Caillard S., Barbier S., et al. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007, 7:2522-2531. SPIESSER Group.
15. Budde K., Becker T., Arns W., et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011, 377:837-847.
16. Weir M., Mulgaonkar S., Pearson T., et al. Mycophenolate mofetil/sirolimus maintenance therapy after calcineurin inhibitor withdrawal in renal transplant recipients: 2-year outcomes of the Spare-the-Nephron (STN) trial. Am J Transplant 2009, 9:200. [Abstract 33].
17. Lebranchu Y., Thierry A., Toupance O., et al. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. American Journal of Transplantation 2009, 9:1115-1123.
18. Schena F.P., Pascoe M.D., Alberu J., et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009, 87:233-242. for the Sirolimus CONVERT Trial Study Group.
19. Diekmann F., Budde K., Oppenheimer F., Fritsche L., Neumayer H.H., Campistol J.M. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004, 4:1869-1875.
20. Bumbea V., Kamar N., Ribes D., et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005, 20:517-523.
21. Gutiérrez M.J., González E., Andrés A., Morales J.M. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction. Transplant Proc 2009, 41:2348-2350.
22. Saurina A., Campistol J.M., Piera C., et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 2006, 21:488-493.
23. van den Akker J.M., Wetzels J.F., Hoitsma A.J. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 2006, 70:1355-1357.
24. Letavernier E., Bruneval P., Vandermeersch S., et al. Sirolimus interacts with pathways essential for podocyte integrity. Nephrol Dial Transplant 2009, 24:630-638.
25. Guba M., von Breitenbuch P., Steinbauer M., et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002, 8:128-135.
26. Oroszlán M., Bieri M., Ligeti N., et al. Sirolimus and everolimus reduce albumin endocytosis in proximal tubule cells via an angiotensin II-dependent pathway. Transplant Immunol 2010, 23:125-132.